Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change
Proc Natl Acad Sci U S A
.
2018 Jun 19;115(25):E5640-E5641.
doi: 10.1073/pnas.1804781115.
Epub 2018 Jun 7.
Authors
Demetrios G Vavvas
1
,
Kent W Small
2
,
Carl Awh
3
,
Brent W Zanke
4
,
Robert J Tibshirani
5
6
,
Rafal Kustra
7
Affiliations
1
Department of Ophthalmology Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114.
2
Macula and Retina Institute, Los Angeles, CA 90048.
3
Tennessee Retina, Nashville, TN 37203.
4
ArcticDx, Toronto, ON M5G 1M1, Canada.
5
Department of Statistics, Stanford University, Stanford, CA 94305; tibs@stanford.edu.
6
Department of Biomedical Data Science, Stanford University, Stanford, CA 94305.
7
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
PMID:
29880713
PMCID:
PMC6016766
DOI:
10.1073/pnas.1804781115
No abstract available
Publication types
Letter
Comment
MeSH terms
Angiogenesis Inhibitors
Disease Progression
Humans
Macular Degeneration*
Pharmacogenetics*
Vascular Endothelial Growth Factor A
Substances
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A